ProfileGDS5678 / 1455199_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 50% 59% 47% 50% 52% 49% 57% 51% 55% 54% 54% 53% 56% 51% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2403750
GSM967853U87-EV human glioblastoma xenograft - Control 23.5486559
GSM967854U87-EV human glioblastoma xenograft - Control 33.1133547
GSM967855U87-EV human glioblastoma xenograft - Control 43.1541450
GSM967856U87-EV human glioblastoma xenograft - Control 53.2092452
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2717449
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5514457
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.2091851
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.358255
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3353454
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3232754
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2776253
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4297756
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2295251